Phase 1 trial of intraperitoneal paclitaxel in patients with gastric adenocarcinoma and carcinomatosis or positive cytology
Paclitaxel may be safely used at intraperitoneal doses of 100 mg/m<sup>2</sup>. Neutropenia associated with weekly treatments was common. Peritoneal complete clinical response rates with multimodality therapy including PTX were promising.
Authors
- Brian D. Badgwell (ORCID: https://orcid.org/0000-0002-9915-8355)
- Jaffer A. Ajani (ORCID: https://orcid.org/0000-0001-9946-0629)
- Jeannelyn S. Estrella (ORCID: https://orcid.org/0000-0003-3705-5964)
- Naruhiko Ikoma (ORCID: https://orcid.org/0000-0002-9825-9234)
- Jitesh D. Kawedia (ORCID: https://orcid.org/0000-0001-9685-9378)
- Jing Li (ORCID: https://orcid.org/0000-0003-0882-9860)
- Xuemei Wang (ORCID: https://orcid.org/0000-0002-4477-1865)
- Xiaoqian Liu (ORCID: https://orcid.org/0000-0002-1650-0654)
- Paul Mansfield
- Mariela Blum
Institutions
- The University of Texas MD Anderson Cancer Center (US)
Publication Details
- Journal
- Cancer
- Published
- 2024-09-17
- DOI
- https://doi.org/10.1002/cncr.35566
- Citations
- 3
- Primary Topic
- Intraperitoneal and Appendiceal Malignancies
- Type
- article
- Field-Weighted Citation Impact
- 1.72